$1.07+2.9%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 9, 2026
Company outlook: revenue of about $175M for Fiscal year 2026 — down 9.0% on a year earlier ($192.2M)
Just reported
From biote Corp.'s results release of November 4, 2026; its quarterly report has since been filed.
Actual
$43.3M
-9.6% y/y
-2.0% q/q
Guided
—
No guide given
Actual
$0.01
-95% y/y
Guided
—
No guide given
Actual
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $43.3M | $48M | -9.64% |
| Profit | $407K | $8.2M | -95.03% |
| Profit per share | $0.01 | $0.22 | -95.45% |
| Free Cash Flow | $1.1M | $13.6M | -91.83% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
biote Corp. reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“While a recent improvement in procedure volume provides early evidence of stabilization in underlying demand, our return to growth is progressing more slowly than anticipated,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Biote advances the healthspan of our Practitioners’ patients by providing innovative hormone optimization and healthy aging solutions. Through our network of Biote certified providers, we collaborate with leading clinicians to restore vitality and promote vibrant aging.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from biote Corp.’s Item 2.02 8-K filed November 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
$2.5M
-70% y/y
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.